Lack of prognostic relevance of alterations in the epidermal growth factor receptor—transforming growth factor-α pathway in human astrocytic gliomas
- 1 October 1996
- journal article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 85 (4) , 634-641
- https://doi.org/10.3171/jns.1996.85.4.0634
Abstract
✓ Alterations in the epidermal growth factor receptor (EGFR) and its main ligand, transforming growth factor-α (TGFα), were investigated for a possible prognostic relevance in 125 astrocytic gliomas (44 World Health Organization (WHO) Grade II, 19 WHO Grade III, and 62 WHO Grade IV tumors). The TGFα and EGFR proteins were detected immunohistochemically using monoclonal antibodies. A positive immunoreaction to TGFa was detected in 33 (75%) of 44 WHO Grade II astrocytomas, 18 (95%) of 19 WHO Grade III astrocytoma, and 50 (81%) of 62 WHO Grade IV glioblastomas. No correlation between TGFα immunoreaction and duration of survival could be found. A positive EGFR immunoreaction was detected in seven (16%) of 44 WHO Grade II astrocytomas, five (26%) of 19 WHO Grade III astrocytomas, and 32 (52%) of 62 WHO Grade IV glioblastomas. Of these gliomas, 97 (26 WHO Grade II, 17 WHO Grade III, and 54 WHO Grade IV gliomas) were examined for EGFR gene amplification using a differential polymerase chain reaction assay. Amplification of the EGFR gene was detected in none of the WHO Grade II astrocytomas, one (6%) of 17 WHO Grade III astrocytomas, and 18 (33%) of 54 WHO Grade IV glioblastomas. Twenty-two of the tumors investigated showed a positive EGFR immunoreaction without detectable gene amplification (five WHO Grade II, four WHO Grade III, and 13 WHO Grade IV tumors). Gene amplification was invariably associated with a positive EGFR immunoreaction. For the entire study group, a strong correlation between EGFR alterations (gene amplification and positive immunoreaction) and survival could be found. However, this correlation only reflected the higher percentages of cases with EGFR alterations in malignant gliomas and was not an independent prognostic factor as determined by multifactorial analysis. These data demonstrate that EGFR alterations are frequent events in astrocytic gliomas and are largely restricted to glioblastomas. However, within one tumor grade they do not provide prognostic information.Keywords
This publication has 40 references indexed in Scilit:
- TP53 alterations and clinical outcome in low grade astrocytomasGenes, Chromosomes and Cancer, 1994
- Amplification of the epidermal‐growth‐factor‐receptor gene correlates with different growth behaviour in human glioblastomaInternational Journal of Cancer, 1994
- Expression of epidermal growth factor receptor in human glioblastoma multiformeBritish Journal Of Neurosurgery, 1993
- Deletion-mutant epidermal growth factor receptor in human gliomas: Effect of type II mutation on receptor functionBiochemical and Biophysical Research Communications, 1991
- Supratentorial anaplastic gliomas in adultsJournal of Neurosurgery, 1989
- Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant gliomaJournal of Neurosurgery, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Neurosurgical management of low-grade astrocytoma of the cerebral hemispheresJournal of Neurosurgery, 1984
- Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cellsNature, 1984
- Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after SurgeryNew England Journal of Medicine, 1980